Business Weekly - Cambridge, UK

Cambridge based Isogenica has acquired the principal assets of Finnish biotech company, Karyon CTT Ltd as well as securing a £2 million cash investment.

Isogenica will acquire the intellectual property portfolio and the laboratory equipment of KCTT. At the same time the Finnish company KC Holding Ltd has, in exchange for a £2 million cash investment, received an unspecified number of Isogenica’s ordinary shares.

Isogenica has developed a powerful in vitro display technology, CIS display, which provides a novel and effective means of rapidly identifying polypeptides that bind with high affinity and fine specificity to any given molecular target.

The technology can also be used for enhancing the in vivo performance of therapeutic and diagnostic peptide products.

Dr Kevin FitzGerald, Isogenica's CEO, said: "It is pleasing that the board and owners of KCTT concluded that Isogenica was an attractive new home for KCTT’s principal assets.

"The cash investment along with the laboratory equipment will significantly strengthen Isogenica’s operations while the IP portfolio contains some compounds that, when further optimized using CIS display could result in the creation of assets with substantial value."

Isogenica was formed in December 2000 to develop and commercializse innovative in vitro molecular evolution technologies. The company has its research facility at the Babraham Research Campus.

Its core technology can be applied to the discovery of new antibody, peptide and polypeptide drug candidates, to the discovery of high specificity diagnostic compounds and to the isolation of target validation and other research reagents, purification and detection reagents.

TrackBack URI for this entry

Comments (0)

Subscribe to this comment's feed